Fatal Outbreak of an Emerging Clone of Extensively Drug-Resistant Acinetobacter baumannii with Enhanced Virulence

Clinical Infectious Diseases

Volumn 61, Issue 2, 2015, Pages 145-154

  Jones, Crystal L ^a   Clancy, Megan ^b   Honnold, Cary ^a   Singh, Shweta ^a   Snesrud, Erik ^a   Onmus Leone, Fatma ^a   McGann, Patrick ^a   Ong, Ana C ^a   Kwak, Yoon ^a   Waterman, Paige ^a   Zurawski, Daniel V ^a   Clifford, Robert J ^a   Lesho, Emil ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b Providence Alaska Medical Center   (United States)

Author keywords

Acinetobacter baumannii; extensively drug resistant; outbreak; virulence

Indexed keywords

CYCLOPHOSPHAMIDE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATION; CHOLECYSTITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLADISTICS; CLINICAL ARTICLE; CLONE; COMORBIDITY; CONTROLLED STUDY; CZECH REPUBLIC; DEATH; DISEASE ASSOCIATION; DISEASE SEVERITY; EPIDEMIC; FEMALE; GENE CLUSTER; GENOMICS; GERMANY; HUMAN; IMMUNOCOMPETENCE; IRON METABOLISM; LUNG INFECTION; MALE; MIDDLE AGED; MOUSE; MULTILOCUS SEQUENCE TYPING; MYELODYSPLASTIC SYNDROME; NONHUMAN; PANCYTOPENIA; PERITONITIS; PHYLOGENY; PNEUMONIA; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN SECRETION; SEPSIS; TYPE IV SECRETION SYSTEM; UNITED STATES; VERY ELDERLY; WOUND INFECTION; ACINETOBACTER INFECTIONS; ANIMAL; CALIFORNIA; CLASSIFICATION; DISEASE MODEL; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MORTALITY; MULTIDRUG RESISTANCE; PATHOGENICITY; STATISTICS AND NUMERICAL DATA; TERTIARY CARE CENTER; VIRULENCE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED, 80 AND OVER; ANIMALS; CALIFORNIA; CZECH REPUBLIC; DISEASE MODELS, ANIMAL; DISEASE OUTBREAKS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GENOMICS; GERMANY; HUMANS; IMMUNOCOMPETENCE; MALE; MICE; MIDDLE AGED; MULTILOCUS SEQUENCE TYPING; PHYLOGENY; TERTIARY CARE CENTERS; UNITED STATES; VIRULENCE;

EID: 84936772293     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ225     Document Type: Article

References (40)

1. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12.
2. Blot S, Vandewoude K, Colardyn F. Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study. Intensive Care Med 2003; 29:471-5.
3. Garnacho J, Sole-Violan J, Sa-Borges M, Diaz E, Rello J. Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med 2003; 31:2478-82.
4. Falagas ME, Kopterides P, Siempos II. Attributable mortality of Acinetobacter baumannii infection among critically ill patients. Clin Infect Dis 2006; 43:389.
5. Hawksworth JS, Stojadinovic A, Gage FA, et al. Inflammatory biomarkers in combat wound healing. Ann Surg 2009; 250:1002-7.
6. Lesho E, Yoon EJ, McGann P, et al. Emergence of colistin-resistance in extremely drug-resistant Acinetobacter baumannii containing a novel pmrCAB operon during colistin therapy of wound infections. J Infect Dis 2013; 208:1142-51.
7. Petersen K, Cannegieter SC, van der Reijden TJ, et al. Diversity and clinical impact of Acinetobacter baumannii colonization and infection at a military medical center. J Clin Microbiol 2011; 49:159-66.
8. Sunenshine RH, Wright MO, Maragakis LL, et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007; 13:97-103.
9. Lee NY, Lee HC, Ko NY, et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 2007; 28:713-9.
10. Lai CC, Hsu HL, Tan CK, et al. Recurrent bacteremia caused by the Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Clin Microbiol 2012; 50:2982-6.
11. McConnell MJ, Actis L, Pachon J. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol Rev 2013; 37:130-55.
12. Joly-Guillou ML, Wolff M, Pocidalo JJ, Walker F, Carbon C. Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem. Antimicrob Agents Chemother 1997; 41:345-51.
13. de Breij A, Eveillard M, Dijkshoorn L, van den Broek PJ, Nibbering PH, Joly-Guillou ML. Differences in Acinetobacter baumannii strains and host innate immune response determine morbidity and mortality in experimental pneumonia. PLoS One 2012; 7:e30673.
14. Jacobs AC, Thompson MG, Black CC, et al. AB5075, a highly virulent isolate of Acinetobacter baumannii, as a model strain for the evaluation of pathogenesis and antimicrobial treatments. MBio 2014; 5:e01076-01014.
15. Luo G, Spellberg B, Gebremariam T, et al. Diabetic murine models for Acinetobacter baumannii infection. J Antimicrob Chemother 2012; 67:1439-45.
16. Lin L, Tan B, Pantapalangkoor P, et al. Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. MBio 2012; 3:e00312.
17. Valentine SC, Contreras D, Tan S, Real LJ, Chu S, Xu HH. Phenotypic and molecular characterization of Acinetobacter baumannii clinical isolates from nosocomial outbreaks in Los Angeles County, California. J Clin Microbiol 2008; 46:2499-507.
18. Harris G, Kuo Lee R, Lam CK, et al. A mouse model of Acinetobacter baumannii-associated pneumonia using a clinically isolated hypervirulent strain. Antimicrob Agents Chemother 2013; 57:3601-13.
19. Schmitt S, McQuillen DP, Nahass R, et al. Infectious diseases specialty intervention is associated with decreased mortality and lower healthcare costs. Clin Infect Dis 2014; 58:22-8.
20. Lesho EP, Waterman PE, Chukwuma U, et al. The antimicrobial resistance monitoring and research (ARMoR) program: the US Department of Defense response to escalating antimicrobial resistance. Clin Infect Dis 2014; 59:390-7.
21. Clifford RJ, Milillo M, Prestwood J, et al. Detection of bacterial 16S rRNA and identification of four clinically important bacteria by realtime PCR. PLoS One 2012; 7:e48558.
22. McGann P, Courvalin P, Snesrud E, et al. Amplification of aminoglycoside resistance gene aphA1 in Acinetobacter baumannii results in tobramycin therapy failure. MBio 2014; 5:e00915.
23. Chuang YC, Sheng WH, Li SY, et al. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with Acinetobacter bacteremia. Clin Infect Dis 2011; 52:352-60.
24. Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011; 173: 676-82.
25. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993; 270:2957-63.
26. Rhee JY, Kwon KT, Ki HK, et al. Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the Acute Physiology and Chronic Health Evaluation II scoring systems. Shock 2009; 31:146-50.
27. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268-81.
28. Villalon P, Valdezate S, Medina-Pascual MJ, Rubio V, Vindel A, Saez-Nieto JA. Clonal diversity of nosocomial epidemic Acinetobacter baumannii strains isolated in Spain. J Clin Microbiol 2011; 49:875-82.
29. Huang H, Yang ZL, Wu XM, et al. Complete genome sequence of Acinetobacter baumannii MDR-TJ and insights into its mechanism of antibiotic resistance. J Antimicrob Chemother 2012; 67:2825-32.
30. Ecker JA, Massire C, Hall TA, et al. Identification of Acinetobacter species and genotyping of Acinetobacter baumannii by multilocus PCR and mass spectrometry. J Clin Microbiol 2006; 44:2921-32.
31. Chen L, Xiong Z, Sun L, Yang J, Jin Q. VFDB 2012 update: toward the genetic diversity and molecular evolution of bacterial virulence factors. Nucleic Acids Res 2012; 40:D641-5.
32. Marti S, Nait Chabane Y, Alexandre S, et al. Growth of Acinetobacter baumannii in pellicle enhanced the expression of potential virulence factors. PLoS One 2011; 6:e26030.
33. Hu D, Liu B, Dijkshoorn L, Wang L, Reeves PR. Diversity in the major polysaccharide antigen of Acinetobacter baumannii assessed by DNA sequencing, and development of a molecular serotyping scheme. PLoS One 2013; 8:e70329.
34. Snitkin ES, Zelazny AM, Montero CI, et al. Genome-wide recombination drives diversification of epidemic strains of Acinetobacter baumannii. Proc Natl Acad Sci U S A 2011; 108:13758-63.
35. Kapitein N, Mogk A. Deadly syringes: type VI secretion system activities in pathogenicity and interbacterial competition. Curr Opin Microbiol 2013; 16:52-8.
36. Weber BS, Miyata ST, Iwashkiw JA, et al. Genomic and functional analysis of the type VI secretion system in Acinetobacter. PLoS One 2013; 8: e55142.
37. Carruthers MD, Nicholson PA, Tracy EN, Munson RS Jr. Acinetobacter baumannii utilizes a type VI secretion system for bacterial competition. PLoS One 2013; 8:e59388.
38. Vinogradov E, Maclean L, Xu HH, Chen W. The structure of the polysaccharide isolated from Acinetobacter baumannii strain LAC-4. Carbohydr Res 2014; 390:42-5.
39. Bruhn KW, Pantapalangkoor P, Nielsen T, et al. Host fate is rapidly determined by innate effector-microbial interactions during Acinetobacter baumannii bacteremia. J Infect Dis 2015; 211:1296-305.
40. Martinez MN, Papich MG, Drusano GL. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/ pharmacodynamic target. Antimicrob Agents Chemother 2012; 56:2795-805.